vs
Side-by-side financial comparison of AMERICAN SUPERCONDUCTOR CORP (AMSC) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $74.5M, roughly 1.7× AMERICAN SUPERCONDUCTOR CORP). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 21.4%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 33.2%).
Anglo American plc is a British multinational mining company with headquarters in London, England. It is the world's largest producer of platinum, representing approximately 40 percent of global output, as well as being a major producer of diamonds, copper, nickel, iron ore, polyhalite and steelmaking coal. The company has operations in Africa, Asia, Australia, Europe, North America and South America.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
AMSC vs TVTX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $74.5M | $129.7M |
| Net Profit | $117.8M | — |
| Gross Margin | 30.7% | 98.0% |
| Operating Margin | 4.5% | -25.0% |
| Net Margin | 158.1% | — |
| Revenue YoY | 21.4% | 73.4% |
| Net Profit YoY | 4679.1% | — |
| EPS (diluted) | $2.62 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $74.5M | $129.7M | ||
| Q3 25 | $65.9M | $164.9M | ||
| Q2 25 | $72.4M | $114.4M | ||
| Q1 25 | $66.7M | $81.7M | ||
| Q4 24 | $61.4M | $74.8M | ||
| Q3 24 | $54.5M | $62.9M | ||
| Q2 24 | $40.3M | $54.1M | ||
| Q1 24 | $42.0M | $41.4M |
| Q4 25 | $117.8M | — | ||
| Q3 25 | $4.8M | $25.7M | ||
| Q2 25 | $6.7M | $-12.8M | ||
| Q1 25 | $1.2M | $-41.2M | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $4.9M | $-54.8M | ||
| Q2 24 | $-2.5M | $-70.4M | ||
| Q1 24 | $-1.6M | $-136.1M |
| Q4 25 | 30.7% | 98.0% | ||
| Q3 25 | 31.0% | 99.0% | ||
| Q2 25 | 33.8% | 98.7% | ||
| Q1 25 | 26.5% | 94.3% | ||
| Q4 24 | 26.6% | 96.6% | ||
| Q3 24 | 28.7% | 97.4% | ||
| Q2 24 | 30.3% | 96.2% | ||
| Q1 24 | 24.8% | 96.4% |
| Q4 25 | 4.5% | -25.0% | ||
| Q3 25 | 4.5% | 15.1% | ||
| Q2 25 | 7.8% | -11.1% | ||
| Q1 25 | 2.5% | -52.2% | ||
| Q4 24 | 2.1% | -81.2% | ||
| Q3 24 | -1.4% | -89.3% | ||
| Q2 24 | -8.2% | -125.1% | ||
| Q1 24 | -5.3% | -336.5% |
| Q4 25 | 158.1% | — | ||
| Q3 25 | 7.2% | 15.6% | ||
| Q2 25 | 9.3% | -11.1% | ||
| Q1 25 | 1.8% | -50.4% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 9.0% | -87.1% | ||
| Q2 24 | -6.3% | -130.1% | ||
| Q1 24 | -3.8% | -328.9% |
| Q4 25 | $2.62 | $0.04 | ||
| Q3 25 | $0.11 | $0.28 | ||
| Q2 25 | $0.17 | $-0.14 | ||
| Q1 25 | $0.04 | $-0.47 | ||
| Q4 24 | $0.06 | $-0.71 | ||
| Q3 24 | $0.13 | $-0.70 | ||
| Q2 24 | $-0.07 | $-0.91 | ||
| Q1 24 | $-0.03 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $141.1M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $536.8M | $114.8M |
| Total Assets | $719.5M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $141.1M | $93.0M | ||
| Q3 25 | $212.9M | $110.9M | ||
| Q2 25 | $207.9M | $75.2M | ||
| Q1 25 | $79.5M | $61.9M | ||
| Q4 24 | $75.2M | $58.5M | ||
| Q3 24 | $72.1M | $36.4M | ||
| Q2 24 | $93.5M | $32.3M | ||
| Q1 24 | $90.5M | $43.3M |
| Q4 25 | $536.8M | $114.8M | ||
| Q3 25 | $342.2M | $73.6M | ||
| Q2 25 | $333.1M | $32.7M | ||
| Q1 25 | $197.1M | $32.8M | ||
| Q4 24 | $192.7M | $59.1M | ||
| Q3 24 | $187.0M | $-30.5M | ||
| Q2 24 | $143.3M | $15.1M | ||
| Q1 24 | $144.6M | $74.1M |
| Q4 25 | $719.5M | $605.2M | ||
| Q3 25 | $445.6M | $538.6M | ||
| Q2 25 | $452.8M | $555.3M | ||
| Q1 25 | $310.5M | $548.8M | ||
| Q4 24 | $310.3M | $594.1M | ||
| Q3 24 | $298.4M | $504.4M | ||
| Q2 24 | $240.1M | $551.1M | ||
| Q1 24 | $232.8M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.2M | $60.7M |
| Free Cash FlowOCF − Capex | $2.4M | — |
| FCF MarginFCF / Revenue | 3.2% | — |
| Capex IntensityCapex / Revenue | 1.2% | — |
| Cash ConversionOCF / Net Profit | 0.03× | — |
| TTM Free Cash FlowTrailing 4 quarters | $16.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.2M | $60.7M | ||
| Q3 25 | $6.5M | $14.3M | ||
| Q2 25 | $4.1M | $5.0M | ||
| Q1 25 | $6.3M | $-42.2M | ||
| Q4 24 | $5.9M | $-35.7M | ||
| Q3 24 | $12.7M | $-42.5M | ||
| Q2 24 | $3.4M | $-40.2M | ||
| Q1 24 | $2.2M | $-119.0M |
| Q4 25 | $2.4M | — | ||
| Q3 25 | $5.1M | $14.2M | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $12.1M | — | ||
| Q2 24 | $3.1M | $-40.3M | ||
| Q1 24 | $1.9M | — |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 7.7% | 8.6% | ||
| Q2 25 | 4.6% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | 22.3% | — | ||
| Q2 24 | 7.8% | -74.5% | ||
| Q1 24 | 4.6% | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | 2.1% | 0.1% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 1.6% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 1.1% | 0.0% | ||
| Q2 24 | 0.7% | 0.2% | ||
| Q1 24 | 0.7% | 0.0% |
| Q4 25 | 0.03× | — | ||
| Q3 25 | 1.37× | 0.56× | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 5.22× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.60× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMSC
| Equipment And Systems | $56.0M | 75% |
| Megatran | $14.1M | 19% |
| Comtrafo Industria De Transformadores Eletricos SA | $4.6M | 6% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
